Biotechnology News
Astellas Pharma has struck a licensing agreement with Sangamo Therapeutics to make use of its neurotropic adeno-associated virus capsid, STAC-BBB. 20 December 2024
Privately-held Certa Therapeutics, a biotech developing precision therapies for fibrotic diseases, has acquired fellow Australian firm OccuRx. 19 December 2024
US pharma giant Merck & Co has announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody. 18 December 2024
Exclusive
Company Spotlight
A clinical-stage immuno-oncology company from Switzerland.
Most Read
26 November 2024
21 November 2024
19 November 2024
In Brief
The Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for the treatment of early Alzheimer’s disease (AD). 5 December 2024
Mergers and Acquisitions
Japanese drugmaker Shionogi has announced that it will acquire full ownership of its joint ventures with subsidiaries of Ping An Insurance. 23 December 2024
19 December 2024
18 December 2024
16 December 2024
13 December 2024
12 December 2024
Editor's Pick
Boardroom
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
French biotech Igyxos Biotherapeutics today announced the appointments of Florent Ferré as chief executive and Dr Elke Bestel as chief medical officer to reinforce its management team and executive committee. 19 December 2024
Swiss immune-oncology specialist Anaveon has appointed Richard Sachse as its chief medical officer (CMO) effective February 1, 2025. 18 December 2024
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze